论文部分内容阅读
目的:探究瑞舒伐他汀强化治疗对行冠状动脉支架置入术后患者再狭窄率、血管内皮功能和血脂水平的影响。方法:选择2013年1月~2015年12月90例于我院行冠状动脉支架置入术后的患者。按照治疗方法的不同将患者随机分为观察组及对照组,每组45例。观察组患者术后给予20 mg/天瑞舒伐他汀强化治疗,对照组患者术后给予常规剂量(5~10 mg/天)瑞舒伐他汀治疗,连续服用6个月。比较两组患者治疗前后的血脂、C反应蛋白(CRP)、白介素8(IL-8)、一氧化氮合酶(e NOS)、内皮素-1(ET-1)水平及术后6个月支架内再狭窄率(ISR)。结果:治疗后,两组患者的胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)水平均较治疗前显著降低(P<0.05),且观察组患者以上指标均显著低于对照组(P<0.05);观察组患者高密度脂蛋白(HDL-C)水平较治疗前增加明显(P<0.05),而对照组该指标无明显改善(P>0.05)。治疗后,两组患者的CRP、IL-8水平均较治疗前显著降低(P<0.05),且观察组患者以上指标显著低于对照组(P<0.05);观察组患者的一氧化氮合酶(e NOS)水平较治疗前显著提高,血管内皮素-1(ET-1)水平显著降低(P<0.05),但对照组以上指标与治疗前相比无明显差异(P>0.05)。术后6个月,观察组患者支架内再狭窄率(ISR)显著低于对照组(P<0.05)。结论:瑞舒伐他汀强化治疗可通过显著改善患者血脂水平,减轻患者机体炎症状态,积极恢复内皮组织损伤,进而预防ISR的发生。
Objective: To investigate the effect of rosuvastatin on restenosis rate, endothelial function and blood lipids in patients undergoing coronary stent implantation. Methods: From January 2013 to December 2015, 90 patients undergoing coronary stenting in our hospital were enrolled. In accordance with the different treatment methods, patients were randomly divided into observation group and control group, 45 cases in each group. Patients in the observation group were given 20 mg / day rosuvastatin intensively after operation, and patients in the control group were given rosuvastatin at the conventional dose (5 ~ 10 mg / day) for 6 months continuously. The levels of serum lipids, C-reactive protein (CRP), interleukin-8, nitric oxide synthase (eNOS) and endothelin-1 (ET-1) In-stent restenosis rate (ISR). Results: After treatment, the levels of TC, TG and LDL-C in both groups were significantly lower than those before treatment (P <0.05), and the above indexes in the observation group (P <0.05). The level of HDL-C in the observation group was significantly higher than that before treatment (P <0.05), but not in the control group (P> 0.05). After treatment, the levels of CRP and IL-8 in both groups were significantly lower than those before treatment (P <0.05), and the above indexes in the observation group were significantly lower than those in the control group (P <0.05); the levels of nitric oxide The level of eNOS was significantly higher than that before treatment and the level of endothelin - 1 (ET - 1) was significantly decreased (P <0.05). However, there was no significant difference between the above indexes in the control group and before treatment (P> 0.05). At 6 months after operation, the in-stent restenosis rate (ISR) in the observation group was significantly lower than that in the control group (P <0.05). Conclusion: Rosuvastatin can improve the level of serum lipids, alleviate the inflammatory state in patients and restore the damage of endothelial tissue, thus preventing the occurrence of ISR.